Search | OpenScholar

Search results

193 results found

The Effects of Genetic Relatedness on the Preterm Infant Gut Microbiota.

Publication: Journal Article

Lim, Shen Jean, Miriam Aguilar-Lopez, Christine Wetzel, Samia O Dutra V, Vanessa Bray, Maureen W Groër, Sharon M Donovan, and Thao Ho. 2021. “The Effects of Genetic Relatedness on the Preterm Infant Gut Microbiota.”. Microorganisms 9 (2).

Melissa Olsen

Person: BS, University of South Florida

Melissa is a dedicated lab assistant who just graduated from the University of South Florida with a Bachelor of Science in biological and biomedical sciences. She joined Dr. Ho’s lab in February 2023 and is now serving as Project Manager on an Anemia R21 study. Her research is centered on...

Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.

Publication: Journal Article

Simuni, T, B Fiske, K Merchant, CS Coffey, E Klingner, C Caspell-Garcia, DE Lafontant, et al. 2021. “Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.”. JAMA Neurol.

Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. NPJ Parkinsons Dis 2021;7:34. doi: 10.1038/s41531-021-00177-8.PMID: 33846349

Publication: Journal Article

Naito, A, AM Wills, TF Tropea, A Ramirez-Zamora, RA Hauser, D Martino, TH Turner, and . 2021. “Expediting Telehealth Use in Clinical Research Studies: Recommendations for Overcoming Barriers in North America. NPJ Parkinsons Dis 2021;7:34. Doi: 10.1038/S41531-021-00177-8.PMID: 33846349”. NP J Parkinsons Dis.

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. doi: 10.1007/s40120-021-00246-3

Publication: Journal Article

Mehta, SH, R Pahwa, CM Tanner, RA Hauser, and R Johnson. 2021. “Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. Doi: 10.1007/S40120-021-00246-3”. Neurol Ther.

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. doi: 10.1002/mds.28702. Epub 2021 Jun 30. PMID: 34191352.

Publication: Journal Article

Videnovic, A, AW Amara, C Comella, PK Schweitzer, H Emsellem, K Liu, AL Sterkel, et al. 2021. “Solriamfetol for Excessive Daytime Sleepiness in Parkinson’s Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. Doi: 10.1002/Mds.28702. Epub 2021 Jun 30. PMID: 34191352.”. Mov Disord.

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3.Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):926-939. doi: 0.1001/jama.2021.10207. PMID: 34519802.

Publication: Journal Article

Hauser, RA, Parkinsons Study Group SURE-PD3 Investigators, and . 2021. “Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3.Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):926-939. Doi: 0.1001/Jama.2021.10207. PMID: 34519802.”. JAMA.

Cenci MA, Riggare S, Pahwa R, Eidelberg D, Hauser RA. Dyskinesia matters. Mov Disord 2020;35:392-396.

Publication: Journal Article

“Cenci MA, Riggare S, Pahwa R, Eidelberg D, Hauser RA. Dyskinesia Matters. Mov Disord 2020;35:392-396.”. 2020. Mov Disord.

Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients with and without Troublesome and Non-Troublesome Dyskinesia. J Parkinsons Dis 2020;10:915-925.

Publication: Journal Article

Hauser, RA, L Zeitlin, S Fisher, and R D’Souza. 2020. “Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients With and Without Troublesome and Non-Troublesome Dyskinesia. J Parkinsons Dis 2020;10:915-925.”. J Parkinsons Dis.

Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. Int J Neurosci 2017;127:841-848.

Publication: Journal Article

Valdes, EG, ML O’Connor, EY Uc, RA Hauser, R Andel, and JD Edwards. 2017. “Use, Maintenance and Dose Effects of Cognitive Speed of Processing Training in Parkinson’s Disease. Int J Neurosci 2017;127:841-848.”. Int J Neurosci.